Cargando…
Engineering Prodrug Nanomedicine for Cancer Immunotherapy
Immunotherapy has shifted the clinical paradigm of cancer management. However, despite promising initial progress, immunotherapeutic approaches to cancer still suffer from relatively low response rates and the possibility of severe side effects, likely due to the low inherent immunogenicity of tumor...
Autores principales: | Yang, Bin, Gao, Jing, Pei, Qing, Xu, Huixiong, Yu, Haijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709995/ https://www.ncbi.nlm.nih.gov/pubmed/33304763 http://dx.doi.org/10.1002/advs.202002365 |
Ejemplares similares
-
Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
por: Gao, Jing, et al.
Publicado: (2020) -
Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery
por: Huang, Lingling, et al.
Publicado: (2022) -
Stimuli-responsive prodrug-based cancer nanomedicine
por: Xie, Angel, et al.
Publicado: (2020) -
Nanomedicine and cancer immunotherapy
por: Yu, Hai-jun, et al.
Publicado: (2020) -
Nanomedicine for Combination Urologic Cancer Immunotherapy
por: Tian, Yun, et al.
Publicado: (2023)